Nautilus Biotechnology is trading at $2.69 (+10.25%) on October 27, 2026, with the earnings beat the strongest identified explanation for the rebound. - Pre-market Q3 loss was $0.12 per share, versus an expected loss of $0.14; revenue of $230,000 topped the $206,250 estimate. - Management reaffirmed plans for platform commercialization, with instrument shipments and assay kits expected by mid-2027. - The move follows a 24.69% decline at the October 26 close, leaving shares volatile.